🧬 Genetic Disorder

Bloom Syndrome

Also known as: Bloom-Torre-Machacek syndrome, Congenital telangiectatic erythema and stunted growth

Bloom syndrome is a rare autosomal recessive genetic disorder characterized by short stature, sun-sensitive skin rash (telangiectatic erythema) on the face, increased susceptibility to infections, and a significantly elevated risk of developing various cancers at a young age. It is caused by mutations in the BLM gene, which is responsible for DNA repair and maintaining genomic stability.

ICD-10: Q82.8 Orphanet: 127 OMIM: 210900
👥 1 in 48,000 Ashkenazi Jews; rarer in other populations Prevalence
🔬 5 Active Trials

Bloom syndrome is a rare problem where kids don't grow very tall, get a sunburn-like rash on their face easily, and have a higher chance of getting sick and getting cancer. It happens because their bodies have trouble fixing broken DNA.

Signs & Symptoms

  • Short stature
  • Facial rash (telangiectatic erythema)
  • Sun sensitivity
  • Increased risk of infections
  • Increased risk of cancer (leukemia, lymphoma, carcinomas)
  • Immunodeficiency
  • High-pitched voice
  • Learning disabilities
  • Male infertility
  • Diabetes

Treatment Options

SUPPORTIVE

Sun protection (sunscreen, protective clothing)

HIGHLY EFFECTIVE
MEDICATION FDA Approved

Infection management (antibiotics, antivirals)

HIGHLY EFFECTIVE
SUPPORTIVE

Cancer surveillance (regular screenings)

MODERATELY EFFECTIVE
THERAPY FDA Approved

Cancer treatment (chemotherapy, radiation, surgery)

MODERATELY EFFECTIVE
THERAPY FDA Approved

Hematopoietic stem cell transplantation (for certain cancers)

MODERATELY EFFECTIVE
THERAPY FDA Approved

Intravenous immunoglobulin (IVIG) therapy (for immunodeficiency)

MODERATELY EFFECTIVE
THERAPY FDA Approved

Growth hormone therapy (for short stature)

MODERATELY EFFECTIVE

Diagnosis

  • Clinical evaluation
  • Physical examination
  • Genetic testing (BLM gene sequencing)
  • Chromosome breakage studies (sister chromatid exchange analysis)

History

Bloom syndrome was first described in 1954 by Dr. David Bloom, a dermatologist, who observed a group of patients with characteristic facial telangiectasia and stunted growth.

Recent Breakthroughs

2022

Improved understanding of BLM helicase function

Research has further elucidated the role of the BLM helicase in maintaining genomic stability and preventing tumorigenesis, providing potential targets for therapeutic intervention.

2023

Development of novel cancer therapies for Bloom syndrome patients

Researchers are exploring targeted therapies and immunotherapies that may be more effective and less toxic for individuals with Bloom syndrome who develop cancer.